Incidence and clinical characteristics of hypertriglyceridemic acute pancreatitis: A retrospective single-center study

Table 2 Comparisons of clinical characteristics and laboratory parameters with different grades of severity of hypertriglyceridemic acute pancreatitis

Characteristic	All (n = 219)	MAP group (n = 29)	MSAP group (n = 114)	SAP group (n = 76)	P value
Sex, n (%)					0.111
Male	140 (63.9)	23 (79.3)	67 (58.8)	50 (65.8)
Female	79 (36.1)	6 (20.7)	47 (41.2)	26 (34.2)
Age, yr	38.92 ± 10.02	38.66 ± 9.73	38.96 ± 10.12	38.96 ± 10.12	0.941
BMI (kg/m2)	26.13 ± 3.30	26.20 ± 1.56	25.58 ± 3.54	28.51 ± 2.97	0.097
Complications, n (%)
Diabetes mellitus	109 (49.8)	14 (48.3)	58 (50.9)	37 (48.7)	0.982
Fatty liver disease	205 (93.6)	25 (86.2)	106 (93.0)	74 (97.4)	0.112
Lipid-lowering treatment, n (%)					< 0.001
Intravenous insulin	84 (38.4)	14 (48.3)	69 (60.5)	1 (1.3)
HP	32 (14.6)	1 (3.4)	26 (22.8)	5 (6.6)
CRRT/HP + CRRT	60 (27.4)	0 (0.0)	1 (0.9)	59 (77.6)
Only anti-lipemic	43 (19.6)	14 (48.3)	18 (15.8)	11 (14.5)
Improved Marshall score	1.00 (0.00, 3.00)	0.00 (0.00, 0.00)	0.00 (0.00, 1.00)	3.00 (3.00, 4.75)	< 0.001
MCTSI score	5.11 ± 1.70	2.14 ± 0.92	5.14 ± 1.06	6.18 ± 1.35	< 0.001
Baseline TG, mg/dL	2713.82 ± 2458.65	1895.15 ± 1685.17	2480.80 ± 2040.458	3386.29 ± 3081.51	0.035
Baseline AMY (nUNL)	2.92 (1.43, 6.41)	2.81 (1.47, 5.21)	2.22 (0.98, 5.08)	5.28 (2.21, 8.66)	< 0.001
CRP, mg/L	196.36 ± 121.97	143.17 ± 97.51	178.65 ± 103.25	247.12 ± 143.73	< 0.001
Albumin, g/L	32.66 ± 5.99	36.48 ± 4.96	34.46 ± 5.16	28.49 ± 5.16	< 0.001
TBIL, mmol/L	16.60 (10.80, 22.90)	18.91 (13.02, 23.68)	15.35 (10.69, 22.46)	16.57 (10.60, 24.92)	0.511
ALT, U/L	20.00 (13.60, 30.70)	21.30 (14.90, 35.75)	20.25 (13.00, 31.93)	19.75 (14.03, 27.30)	0.648
AST, U/L	25.00 (17.50, 39.50)	21.30 (17.00, 28.05)	20.00 (16.08, 30.63)	36.55 (25.00, 56.80)	< 0.001
Total cholesterol, mmol/L	8.58 ± 4.56	7.47 ± 2.96	8.82 ± 4.53	8.64 ± 5.06	0.522
HDL-C, mmol/L	0.82 (0.61, 1.10)	0.88 (0.75, 1.17)	0.86 (0.66, 1.16)	0.69 (0.52, 0.99)	0.241
LDL-C, mmol/L	2.92 ± 1.55	3.77 ± 1.41	2.91 ± 1.58	2.62 ± 1.46	0.003
Glucose, mmol/L	10.50 ± 3.64	9.47 ± 3.70	10.34 ± 3.54	11.13 ± 3.69	0.100
Urea nitrogen, mmol/L	4.73 ± 3.31	4.56 ± 1.63	3.66 ± 1.76	6.40 ± 4.64	< 0.001
Creatinine, μmol/L	83.03 ± 66.48	71.90 ± 18.03	65.46 ± 19.11	113.63 ± 103.46	< 0.001
Calcium, mmol/L	1.93 ± 0.31	2.16 ± 0.18	2.00 ± 0.21	1.75 ± 0.37	< 0.001
WBC, × 109/L	11.67 ± 4.10	11.22 ± 3.64	11.99 ± 4.06	11.37 ± 4.33	0.351
PLT, × 109/L	200.19 ± 69.19	194.69 ± 73.58	208.67 ± 65.17	189.57 ± 72.51	0.159
Hb, g/L	141.11 ± 24.52	143.69 ± 19.12	136.87 ± 22.76	146.49 ± 27.78	0.010
STSH, mIU/L	0.28 (0.16, 0.65)	0.49 (0.28, 0.98)	0.28 (0.14, 0.66)	0.24 (0.16, 0.62)	0.188
FT3, pmol/L	2.29 ± 1.00	2.90 ± 0.77	2.36 ± 0.86	2.89 ± 1.18	0.018
FT4, pmol/L	12.56 ± 3.70	12.83 ± 2.10	12.88 ± 3.95	12.11 ± 3.68	0.302
Admission to ICU, n (%)	98 (44.7)	1 (3.4)	27 (23.7)	70 (92.1)	< 0.001
Death, n (%)	9 (4.1)	0 (0.0)	0 (0.0)	9 (11.8)	< 0.001

MAP: Mild acute pancreatitis; MSAP: Moderately severe acute pancreatitis; SAP: Severe acute pancreatitis; BMI: Body mass index; HP: Hemoperfusion; CRRT: Continuous renal replacement therapy; MCTSI: Modified computed tomography severity index; TG: Triglyceride; AMY: Amylase; UNL: Upper limit of normal; CRP: C-reactive protein; TBIL: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate transaminase; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; WBC: White blood cell; PLT: Blood platelet; Hb: Hemoglobin; STSH: Sensitive thyrotropin; FT3: Free triiodothyronine; FT4: Free thyroxine; ICU: Intensive care unit.